CoChat
Sign Up
Cited by 574Protein Kinase Regulation and GTPase SignalingCancer Mechanisms and TherapyComputational Drug Discovery Methods

The DOI matches its Crossref record; 225 of the 225 references it cites were found in a registry or an index.

Properties of FDA-approved small molecule protein kinase inhibitors

Roskoski, Robert·2019·Pharmacological Research
DOI 10.1016/j.phrs.2019.03.006
Open this paper in CoChat — free account

Abstract

Because mutations, overexpression, and dysregulation of protein kinases play essential roles in the pathogenesis of many illnesses, this enzyme family has become one of the most important drug targets in the past 20 years. The US FDA has approved 48 small molecule protein kinase inhibitors, nearly all of which are orally effective with the exceptions of netarsudil (which is given as an eye drop) and temsirolimus (which is given intravenously). Of the 48 approved drugs, the majority (25) target receptor protein-tyrosine kinases, ten target non-receptor protein-tyrosine kinases, and 13 target protein-serine/threonine protein kinases. The data indicate that 43 of these drugs are used in the treatment of malignancies (36 against solid tumors including lymphomas and seven against non-solid tumors, e.g., leukemias). Seven drugs are used in the treatment of non-malignancies: baricitinib, rheumatoid arthritis; fostamatinib, chronic immune thrombocytopenia; ruxolitinib, myelofibrosis and polycythemia vera; nintedanib, idiopathic pulmonary fibrosis; sirolimus, renal graft vs. host disease; netarsudil, glaucoma; tofacitinib, rheumatoid arthritis, Crohn disease, and ulcerative colitis. Moreover, ibrutinib and sirolimus are used for the treatment of both malignant and non-malignant diseases. The most common drug targets include ALK, B-Raf, BCR-Abl, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptor (VEGFR). Most of the small molecule inhibitors (45) interact directly with the protein kinase domain. In contrast, sirolimus, temsirolimus, and everolimus are larger molecules (MW ≈ 1000) that bind to FKBP-12 to generate a complex that inhibits mTOR (mammalian target of rapamycin). This review presents the available drug-enzyme X-ray crystal structures for 27 of the approved drugs as well as the chemical structures and physicochemical properties of all of the FDA-approved small molecule protein kinase antagonists. Six of the drugs bind covalently and irreversibly to their target. Twenty of the 48 drugs have molecular weights greater than 500, exceeding a Lipinski rule of five criterion. Excluding the macrolides (everolimus, sirolimus, temsirolimus), the average molecular weight of drugs is 480 with a range of 306 (ruxolitinib) to 615 (trametinib). Nearly half of the antagonists (23) have a lipophilic efficiency with values of less than five while the recommended optima range from 5-10. One of the vexing problems is the near universal development of resistance that is associated with the use of small molecule protein kinase inhibitors for the treatment of cancer.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2019.03.006

Cites

225 of 225 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Roskoski, 2016, Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases, Pharmacol. Res., 111, 784, 10.1016/j.phrs.2016.07.038 · DOI

Cited by

Sorted by citations

See all 574

Related

See all

Metadata

Authors
Roskoski, R.
Corresponding author
Roskoski, Robert
ORCID
Roskoski, Robert
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2019-06
Volume
144
Pages
19-50
ISSN
1043-6618 (ISSN-L)
DOI
10.1016/j.phrs.2019.03.006
OpenAlex
W2922159934
Cited by
554
References
225
Citations by year
2026: 36 · 2025: 42 · 2024: 60 · 2023: 43 · 2022: 64 · 2021: 153 · 2020: 109 · 2019: 47
FWCI
8.52
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Pharmacological Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
protein kinase inhibitors, small-molecule kinase inhibitors, FDA-approved drugs, physicochemical properties, molecular weight, Lipinski's rule of five, kinase domain, mTOR inhibition, rapamycin, temsirolimus, everolimus, receptor tyrosine kinase, non-receptor tyrosine kinase, serine/threonine kinase
MeSH terms
Animals, Humans, Models, Molecular, Protein Conformation, Protein Kinases, United States, United States Food and Drug Administration, Drug Approval, Crystallography, X-Ray, Protein Kinase Inhibitors, Small Molecule Libraries, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review